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Abstract 
 
Traditional herbal medicines are now increasingly being appreciated with Western models of integrative health 
sciences and evidence-based approach both in the basic research and clinic scenario. Ashwagandha is a commonly 
used plant in Ayurvedic, Indian traditional medicine. Medicinal value of Ashwagandha (WithaniasomniferaDunal) 
extends from anti-inflammatory, anti-arthritic, anti-rheumatic, rejuvenation and anti-cancer. Based on the belief 
that holistic multi-site mechanism of action offers greater chance of success, the traditional Ayurvedicmedicine 
practices the use of whole herb or its crude extract. It opposes with the mainstream of pharmaceutical industry that 
uses single and purified molecules. In the present study, we used bioinformatics approach to reveal the mechanism 
of action of (i) crude extract of Ashwagandha leaf extract and its purified components, (ii) Withanone and (iii) 
Withaferin A. Whereas p53-p21 was identified as a common signaling pathway for the three kinds of reagents, 
specific signaling pathways for Withaferin-A and Withanone were identified. Whereas the crude extract and 
Withanone were selectively toxic to human cancer cells, WithaferinA showed cytotoxicity to the normal cells too. 
The study suggested that the crude extract or a combinational formulamay be a superior and safenatural reagent for 
cancer treatment. 
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Introduction 
 
Estimated 80% of the world population still 
has no access to modern medicine [2] and rely on 
traditional home medicine treatments using a 
variety of herbs. Ashwagandha (Withaniasomnifera) 
is widely used in Indian natural medicine, 
Ayurveda that constitutes one of the world’s 
oldest system of hoe medicine. Extracts from 
different parts of Ashwagandha have been 
claimed to be valuable for remedies for stress, 
inflammation, arthritic, antidepressant, 
immunostimulation, adaptogenic, cardio-
protection, rejuvenation, and regeneration [7, 1, 3, 
4, 8]. Ayurvedic medical system practices the use 
of dry powder or crude extract in contrast to  the 
modern medicine that relies on single molecules 
or pure compound.  It is widely believed that the 
crude extracts  may   offer     ystemic   curing  
 
 
 
 
 
 
 
 
 
mechanism, multi-site mechanisms of action 
from complex active compounds and hence 
provide greater chances for success than a single 
agent [9]. However, the mechanisms and the 
multiple target approach lacks laboratory 
validation.We undertook a bioinformatics study 
to reveal the mechanism of action of the crude 
extract and purified components of the 
Ashwagandha leaves.  Aswagandha in comparing 
gene regulatory circuits in a crude extract 
preparation vis-à-vis some of its bioactive 
components.  
Initially, gene targets of the crude extract and 
its purified components were identified by gene 
silencing approach using human cell culture as a 
model.  In this model, cells were transfecetd with 
gene silencing small molecules such as siRNA 
ribozyme and then treated with the crude extract 
or purified component. Effect of the extractand 
purified molecules is compared in the control and 
gene-silenced cells by cell viability assays.  By this 
assay, the genes of which the silencing abrogated 
the effect of crude extract or the components 
were selected as candidate gene targets. List of 
such identified targets was then analyzed by 
bioinformatics tool "Ingenuity Pathway Analysis" 
to explore how the identified gene targets interact 
functionally with each other. We found that 
crude extract and their purified components act 
through different pathways. WithaferinA caused 
*Corresponding address: 
 Renu Wadhwa  
AIST Tsukuba Central 4  
1-1-1 Higashi, Tsukuba,  
Ibaraki 305-8562, Japan 
Email: renu-wadhwa@aist.go.jp 
+81-29-861-2521 
 
Full Article : Gene target of  Withania somnifera  
 
[2] J.Trop.Life.Science.  Vol I. No 1. Oct, 2010 
 
 
induction of pathways that signified higher 
toxicity. In contrast to this, Withanone and the 
crude extract caused were less toxic suggesting 
that crude extract may be a safer approach. 
 
Materials and Methods 
 
Preparation of crude extract from Ashwagandha. 
 
Ashwagandha (W. somnifera) leaf extracts were 
prepared as described earlier [5]. The leaves were 
air dried, ground to a fine powder, and subjected 
to extraction with methanol (60°C) in Soxhlet 
apparatus for 4 to 5 days. The methanol extracts 
were further extracted with hexane to remove 
chlorophyll and other pigments and then with 
diethyl ether that was evaporated to obtain the 
ether extract. Ether extract solubilized in DMSO 
was used for the present studies. Whereas, 
Withanone and Withaferin A have been 
purchased from Cromadex, USA. 
 
Pathway analysis by gene silencing approach  
 
shRNAs for several genes as described earlier 
[14]   were cloned in a U6 driven expression 
vector as described earlier (Wadhwa, et al., 2004). 
Osteogenic sarcoma (U2OS) cells were plated in 
96-well plates, cultured in DMEM (Life 
Technologies, Gaithersburg, MD), supplemented 
with 10% fetal bovine serum in a humidified 
incubator (37°C and 5% CO2). Cells (∼50-60% 
confluency) were transfected with 50 ng of the 
plasmid DNA. After 48 h, cells were treated with 
crude extract (6 lg/ml), withaferin A (1.5 lM) and 
Withanone (25 lg/ml). Cell viability was 
measured by Alamar BlueTM assay 
(BioSourceInterna- tional, USA). Empty shRNA 
vector was used as a control. The shRNAs that 
abrogated the killing effect of i-Extract and its 
fractions were considered as involved in their 
effect and were analyzed for pathways by 
Ingenuity Pathways Analysis software  
(www.ingenuity.com). 
 
Results and Discussion 
 
Function of candidate target gene and the 
possible mechanism of toxicity of crude and its 
fractions were analyzed by Ingenuity Pathways 
Analysis (Ingenuity System, www.ingenuity.com) 
(Figure 1). The gene silencing based citotoxicity 
analysis revealed that the crude Extract and its 
components have different pattern in killing 
mechanism of cancer cell (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Diagram off functional genomic assays were employing 
small hairpin RNA (shRNA; siRNA Library) to identified gene 
targets of crude extract of Ashwagandha, withanone and withaferin 
A. MCF-7 were grown in 96 well plate (1) for 24 h, then were 
transfected with siRNA library(2). After 12 h, cells were splite into 3 
plate (3) and treated with the respective drugs (4). After 24 h 
exposure to the crude extracts, gene targets were identified based on 
dead (Blue) or live cell (red) (5). The target genes been used to 
performed cytotocitiy  analysis using IPA software. 
 
 
Taken together, the data revealed that crude 
extract kill cancer cells through 3 pathways: cell 
cycle G2/M, Oxidative stress and p53 Signaling.  
In addition to these pathways, Withanone 
appeared to cause induction of Apoptosis, and  
Oxidative stress signaling. Withaferin A also 
caused induction of NF-kappaB that was not 
significant in the Withanone treated cells. 
Interestingly, whereas crude extract and its 
compounds seemed to affect in different 
pathways, p53 signaling was identiﬁed as one of 
the common pathways. We examined p53 activity 
in the cells and found that infact p53 was 
activated by treatment of cells with crude extracts 
well as the pure components. Mechanism of such 
activation was also attempted. The activity of 
wild-type p53 is regulated by multiple factors, 
including its interactions with binding partners. 
In transformed cells, mortalin, a hsp70 family 
member, interacts and inactivates p53 by 
sequestering it in the cytoplasm [6]. We found 
that in cells treated with crude extract and its 
compnents, p53-mortalin complexes are 
abrogated and there is a significant increasein the 
nuclear translocation of p53 and shift of mortalin 
staining from the perinuclear to 
pancytoplasmicpattern (Figure 3). 
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Figure 2.  Cytotoxicity Mechanism Comparisons of crude extracts, 
Withanone and WithaferinA. Crude extract showed greater 
selectivity than others, which is statistically impacted on only three 
pathways, whereas the effects of Withanone and WithaferineA were 
more spread. 
 
Such shift in thestaining pattern of mortalin and 
increase in p53 has earlier been demonstrated to 
be associated with the induction of senescence in 
cancer cells [11,12]. Based on these findings, we 
concluded that the three kind of compounds 
cause senescence in cancer cells. These ﬁndings 
suggested that crude extract of Ashwagandha, 
WithaferinA, Withanonedisrupt mortalin-p53 
interactions and thus act as anti-mortalin 
molecules resulting in reactivation of p53 
function.  
We next tested the effect of three 
components on normal human cells by the 
similar approach. As shown in Figure 4, we 
found that whereas the crude extract and 
Withanone were nontoxic to normal cells, 
Withaferin A was toxic [15]. It caused activation 
of p53 in normal cells that was associated with 
the acticvation of its downstream regulator p21. 
Both the crude extractand Withanone did not 
cause induction of p53 or p21 in normal cells. 
 
 
 
 
 
Figure 3. Common pathways targeted by crude extract, 
withaferinAdanWithanone.  It showed that the BRCA1 is key target 
gene to stop cell cycle progession (A) trough activation of p53 
function (C) and caused a shift in the staining pattern of mortalin 
(red) from perinuclear to pancytoplasmic), p53 was translocated into 
the nucleus of cancer cells (green nuclear staining) (B). 
 
In fact, p21 was seen as down-regulated 
suggested that such suppression of p53-p21 in 
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normal cells may cause their rejuvenation. We 
tested this by a variety of molecular markers and 
lifespan studies and found that indeed the cells 
cultured in Withanone-supplemented medium 
have lower degree of molecular damage and are 
protected against the oxidative damage [14,15]. 
The cells cultured in Withanone supplemented 
medium showed lifespanextension suggesting 
that Withanone is a candidate anti-aging reagent. 
 
 
 
Figure 4. Withaferin have more toxicity activity in normal 
cell (TIG-1) (4) then withanone (3), Crude extract (2) and 
control (1).  
 
By using a combined gene-silencing and 
bioinformatics approach, we have found that the 
crude extract and its components differ in their 
bioactivity and the mechanism of action. 
Whereas Withaferin A is toxic to normal cells, 
thecrude extract did not cause toxicity suggesting 
that Withanone is natural antidote of Withaferin 
A.   
 
Conclusion 
 
Ashwaganda (W. somnifera)leaf extract kills 
cancer cells selectively. Its components, 
Withaferin A and Withanone have different gene 
targets and mechanism of action. Whereas 
Withaferin A caused toxicity to normal cells, 
Withanone was safe and hence can be recruited 
in safe cancer therapeutics.Furthermore, the 
combinational approach for Withaferin A and 
Withanone for anticancer, antiaging effects for 
cancer and normal cells, respectively is warranted. 
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